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Editors’ NotesDefining Pluripotency
At the end of last year, Cell Stem Cell published a Protocol Review article from Maherali and Hochedlinger in which the authors
outlined the procedures used to generate induced pluripotent stem cells (iPSCs) from lineage-restricted somatic populations. The
main intention of the article was to offer guidance to readers interested in pursuing this exciting line of research, but the authors
also included their own recommendations as to how to assess whether a candidate line had ‘‘earned’’ the designation of iPSC.
Perhaps not surprisingly, the issue of how pluripotent cells are defined, and what criteria should be used for their analysis, has raised
comments and questions from additional experts in the field. In this issue, we present two Letters from groups of researchers working
in the iPSC field that continue the discussion of how pluripotency can, or should, be defined. Daley et al. expand on the rationale of
why the most stringent measures available should be applied prior to publishing a novel iPSC line, whereas Ellis et al. propose that not
all circumstances call for functional, in vivo demonstrations of pluripotency. Clearly, this rapidly expanding field would benefit from
a collective set of consensus guidelines, as Maherali and Hochedlinger indicate in their Response.
Targeting Regeneration, Inside and Out
Two research articles in this issue describe distinct strategies toward developing regenerative therapies. In the first case, Rafii and
colleagues study the regeneration of bone marrow vascular networks damaged during chemotherapy or irradiation and demonstrate
that the VEGF-dependent recovery of sinusoidal endothelial cells is specifically required for efficient hemato-
poietic reconstitution. In a second report, Olwin and coauthors restore damaged skeletal muscle fibers by
transferring a purified satellite-SP population derived from healthy muscle tissue. Importantly, the trans-
planted muscle progenitors repopulate the primitive pool of SP-satellite cells in addition to giving rise to
myofibers, and the progenitors maintain their functional capacity even after reisolation and secondary
transplantation. In some situations, it may be preferable to transfer candidate therapeutic populations via
the bloodstream, rather than physically targeting the regenerative cells to the tissue of interest. This month’s
Review article examines how MSC populations can travel through the body, largely after systemic injections.
Karp and Leng cover what is known currently, and what important questions remain to be tackled in terms of
when and how MSC trafficking can be controlled and perhaps exploited for therapeutic goals.
Cancer Stem Cells—Beyond the Name
Another ‘‘hot’’ topic in the stem cell world is the issue of cancer stem cells. For a seemingly simple-sounding term, this label still
generates a surprisingly large amount of disagreement. A variety of reviews and commentary articles have appeared on the subject,
and given the ever-increasing pace of primary publications that examine cancer stem cell populations, that trend seems unlikely to
change. However, as discussed by Craig Jordan in this month’s Forum article, it seems time for the field to move past its largely
semantic disagreements and get to the heart of the confusion plaguing the field. The important issue, as underscored by the author,
is to consider what aspects of our understanding about stem cell behavior can inform the pursuit of improved cancer therapies.
Illustrating this overall approach, a Research Article in this issue from Holland and colleagues reports that a subpopulation of
tumor-forming glioma cells depend on Akt signals to maintain high expression levels of ABCG2. The activity of this transporter leads
to the ‘‘side population’’ (SP) phenotype observed in glioma and other stem cell populations. Importantly, while temozolomide is used
as a standard clinical therapy for glioma, exposure to this drug elevates the frequency of SP cells in tumor samples. This finding
suggests that, after treatment, patients may exhibit an increased risk of tumor recurrence due to residual ABCG2+ cells.
Refining Responsive Populations
The opportunity to generate therapeutic populations of cells in vitro is one of the founding principles of regenerative medicine, and in
this issue, Bhatia and colleagues shed some light onto signaling pathways that participate in the development and expansion of
hematopoietic cells from ESC cultures. Interestingly, their results discriminate distinct roles for canonical
and noncanonical Wnt pathway activation during this process and may aid in fine-tuning culture conditions
that will lead to efficient generation of HSC populations from pluripotent cells. Also in this issue, Sommer
and coauthors offer a different perspective as to how stem cell populations are regulated by specific signaling
cascades. In their study, the authors provide insight into the differing effects of Rho GTPase signals on NSC
populations present at distinct developmental stages and reveal that only relatively late-stage nonmigrating
neural precursors are responsive to proliferative cues triggered by EGF. Improved understanding of the impact
of in vivo developmental cues, when delivered in context, may also help design culture protocols that yield
more homogeneous populations of functional neural progenitors.Cell Stem Cell 4, March 6, 2009 ª2009 Elsevier Inc. xi
